Autoantigen microarrays reveal myelin basic protein autoantibodies in morphea

Table 1 Clinical characteristics of morphea participants with MBP autoantibodies

Parameter	MBP-positive	MBP-negative	P value^b
Total, No (%)	50 (71.4%)	20 (28.5%)
Age, median (IQR), years	43 (19–63)	41 (25–59)	0.75
Sex, F/M, No	46F/4 M	16F/4 M	0.21
Ethnicity: White, No (%)	36 (72.0%)	16 (80.0%)	0.56
Morphea subtype:			0.14
Generalized, No (%)	24 (48.0%)	11 (55.0%)
Linear, No (%)	20 (40.0%)	4 (20.0%)
Plaque, No (%)	4 (8.0%)	5 (25.0%)
Mixed, No (%)	2 (4.0%)	0 (0%)
LoSCAT component scores:	n = 25	n = 11
mLoSSI, median (IQR)	26 (6–48)	11 (9–20)	0.61
LoSDI, median (IQR)	22 (8–30)	10 (7–23)	0.45
Lesional Pain, No (%)^a			0.39
Yes	19 (38.0%)	5 (25.0%)	1
No	25 (50.0%)	12 (60.0%)
Lesional Itch, No (%)^a
Yes	29 (58.0%)	12 (60.0%)
No	15 (30.0%)	5 (25.0%)

IQR, interquartile range, LoSCAT, localized scleroderma cutaneous assessment tool, mLoSSI, modified localized skin severity index, LoSDI, localized scleroderma damage index
^aPatient-reported itch and pain scores available for 44 of 50 MBP-positive and 17 of 20 MBP-negative morphea patients
^bCategorical variables compared using Fisher’s Exact test. Continuous variables were compared between clusters using Mann–Whitney test